Boston hospital giant-backed CorticoMetrics gains FDA clearance for AI neuroimaging software

Boston-based CorticoMetrics has received U.S. Food and Drug Administration clearance for its novel artificial intelligence software used for assessing neurological disorders, the company announced on Wednesday.

The AI product, known as THINKQ, automatically segments T1-weighted MRI brain scans, quickly reporting volumetric measurements and views of 30 key brain structures. These data points are then compared to age- and gender-matched information.

"THINQ reporting aids the workflow of radiologists and neurologists, aiming to increase examination throughput and improve the overall quality of patient outcomes," Nick Schmansky, co-founder and CEO of the firm, said in a statement.

Reports generated by the 510(k)-cleared software include brain images with color-coded segmentations and plots showing how measurements compare to reference metrics. Segmentations are available in DICOM format as JPEG images, the company noted.

CorticoMetrics was founded in 2012 to commercialize neuroimaging analysis software developed at Massachusetts General Hospital.